Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (488)	6/15/1999 9:25:00 PM
From: Neal davidson	Respond to of 550

If you want to continue the buyout streak, you might want to consider Liposome (LIPO) which also has promising cancer options. It also has earnings.

To: Miljenko Zuanic who wrote (488)	6/15/1999 9:45:00 PM
From: LLCF	Respond to of 550

Miljenko and all, congratulations...! not exactly a grand slam, but sound analysis and persistence has yielded fantastic returns! Well done. DAK

To: Miljenko Zuanic who wrote (488)	6/21/1999 12:27:00 PM
From: gao seng	Read Replies (2) \| Respond to of 550

New Concept Of Tumor Growth Suggests Tumors Coopt Existing Host Vessels In Initial Stages Posted on June 21, 1999 06:33 AM PDT WESTPORT, Jun 18 (Reuters Health) - The decade-old theory that holds that tumors begin as avascular masses and grow to a certain point without the aid of host blood vessels has been challenged by a group of scientists in New York. "What we've realized is that tumors grow very much differently than that," Dr. George D. Yancopoulos, chief scientist at Regeneron Pharmaceuticals in Tarrytown, told Reuters Health."What's really going on is that there is an immediate ongoing battle for blood vessels between the tumor and the normal healthy tissue. Tumors immediately abduct or coopt existing blood vessels and try to make them their own.This happens right away," he said. Dr. Yancopoulos and colleagues from Regeneron and New York University describe their studies on tumor angiogenesis in the June 18th issue of the journal Science. The scientists also found in their experiments using the rat glioma model and human glioblastomas that the host does not sit idly by, as previously thought. "The host defense turns on an angiogenic antagonist, angiopoietin-2, and that kills off blood vessels that the tumor has taken over," Dr. Yancopoulos told Reuters Health."It's sort of suicide of the body's own blood vessels to save the body from being taken over by the tumor as a way to kill off the tumor. When you have a successful tumor, the tumor itself mounts a secondary response and overcomes the defense mechanism of the host." The data "...really substantiate the critical roles of two growth factor families--the VEGF family that has been long studied and the more recently identified family of angiopoietins," Dr. Yancopoulos told Reuters Health."These two families are working together seemingly to regulate both the host defense suicide process as well as the ultimate secondary response to tumors." The findings make both the VEGFs and the angiopoietins "...interesting targets for antitumor therapies," Dr. Yancopoulos said.The anti-VEGF approach is one that is being actively studied, Dr. Yancopoulos said.His group's findings show that scientists "...should be aggressive about anti-VEGF therapies..." as well as the angiopoietins, "...which have been relatively unexplored because they are so recently discovered." Science 1999;284:1994-1998.